Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Proteomics01:33

Proteomics

9.0K
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model.

Molecular oncology·2026
Same author

Findings from the PM4Onco Workshop on Determining Patient Similarity Search Strategies for Personalized Therapy in Molecular Tumor Boards.

Studies in health technology and informatics·2026
Same author

ATM Deficiency Induces TGF-β-Mediated Stromal Programming in Pancreatic Cancer.

Cancer research·2026
Same author

Clinically actionable genomic and transcriptomic landscape of advanced neuroendocrine neoplasms.

Med (New York, N.Y.)·2026
Same author

GLYATL1 is associated with metabolic and epigenetic changes and with endocrine resistance in luminal breast cancer.

Clinical epigenetics·2026
Same author

Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II Trial.

International journal of cancer·2026
Same journal

Geographical Pattern of Testicular Cancer Points to Maternal Exposures Behind Increasing Incidence.

International journal of cancer·2026
Same journal

High Endothelial Venules in Small Cell Lung Cancer: Prognostic Subtypes and Therapeutic Implications for Immunoradiotherapy.

International journal of cancer·2026
Same journal

Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1-5 and Therapeutic Implications in Neuroendocrine and Non-Neuroendocrine Malignancies.

International journal of cancer·2026
Same journal

Sex Hormone Receptors, HBV Integrations and Their Prognostic Predictive Value Among Hepatocellular Carcinoma Patients.

International journal of cancer·2026
Same journal

MET Expression in Upper Gastrointestinal Adenocarcinoma: Prevalence, Prognostic Impact, and Implications for Anti-MET Antibody-Drug Conjugate Therapy.

International journal of cancer·2026
Same journal

Leveraging Minimal Variables for Maximal Screening Yield: A Global Equity Perspective on Colorectal Cancer Risk Stratification.

International journal of cancer·2026
See all related articles

Related Experiment Video

Updated: Dec 8, 2025

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
08:08

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors

Published on: February 27, 2015

16.8K

Integrating proteomics into precision oncology.

Leonie W Wahjudi1, Stephan Bernhardt1, Khalid Abnaof1

  • 1Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.

International Journal of Cancer
|September 19, 2020
PubMed
Summary
This summary is machine-generated.

Integrating DNA, RNA, and protein analysis in cancer improves patient stratification. This multi-omics approach refines precision cancer therapy by revealing protein activities that explain clinical outcomes and treatment responses.

Keywords:
genomicsprecision oncologyproteomicstherapeutic decision making

More Related Videos

Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification
10:37

Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification

Published on: November 15, 2017

12.5K
A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
09:00

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions

Published on: April 18, 2025

1.1K

Related Experiment Videos

Last Updated: Dec 8, 2025

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
08:08

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors

Published on: February 27, 2015

16.8K
Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification
10:37

Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification

Published on: November 15, 2017

12.5K
A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
09:00

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions

Published on: April 18, 2025

1.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Proteomics

Background:

  • Precision oncology utilizes DNA and RNA sequencing for targeted cancer treatment.
  • Molecular tumor boards assess genetic alterations to guide therapy selection.
  • There is a need for deeper patient characterization beyond genomic data.

Purpose of the Study:

  • To assess the abundance and activity of 27 proteins in 134 cancer patients.
  • To evaluate the utility of proteomic data in refining treatment recommendations within the MASTER program.
  • To explore the integration of proteomic data with DNA and RNA sequencing for enhanced cancer therapy.

Main Methods:

  • Proteomic and phosphoproteomic analysis of 27 targets in 134 tumor samples.
  • Selection of targets based on relevant therapeutic baskets in the MASTER program.
  • Integrative analysis of DNA, RNA, and protein data.

Main Results:

  • Proteomic data supported DNA/RNA-based treatment recommendations in 10-57% of cases.
  • Protein activities frequently suggested alternative therapeutic options.
  • Protein activities correlated with patient clinical course and treatment failure.

Conclusions:

  • Integrative analysis of multi-omics data (DNA, RNA, protein) can refine patient stratification in precision oncology.
  • Proteomic profiling holds potential to increase the success rate of precision cancer therapy.
  • Prospective validation studies are necessary to integrate proteomic analysis into routine clinical practice.